Description

CJC-1295 without DAC is a growth hormone-releasing hormone analogue studied within endocrine and peptide research. Unlike the DAC-modified variant, this formulation is investigated without the drug-affinity complex, providing researchers with a distinct peptide profile for studying growth hormone-related signalling. Research explores its relationship with growth hormone activity, IGF-1 pathways, and broader endocrine mechanisms. Its connection to growth hormone signalling has also made CJC-1295 relevant to research investigating biological ageing and longevity-associated processes. This formulation contains 10mg across 10 vials and is supplied for controlled laboratory investigation into growth hormone pathways, endocrine signalling, IGF-1 mechanisms, and related cellular processes.